TransMedics Group, Inc.
Financials
Valuation Metrics
TransMedics Group, Inc.'s Market Cap is $2.33B. At end of 2025 it was $4.16B. Ranked #1881 of 3,118 in US market (top 60%), #688 of 1,474 on NASDAQ (top 47%), #115 of 203 in Health Care Equipment & Services (top 57%) by Market Cap.
Investment Metrics(as of 2026-11-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $2.33B | US#1,881/3,118 Sec#115/203 |
| Revenue | $668M | US#2,115/3,118 Sec#132/203 |
| Net Income | $152M | US#1,424/3,118 Sec#72/203 |
| Total Assets | $1.46B | US#2,266/3,118 Sec#116/203 |
| Net Assets | $518M | US#2,208/3,118 Sec#113/203 |
| Employees | 898 | US#2,034/3,118 Sec#141/203 |
| Value | ||
| P/E | 15.36x | US#779/3,118 Sec#12/203 |
| P/B | 4.50x | US#2,124/3,118 Sec#121/203 |
| PEG | 0.14x | US#240/3,118 Sec#10/203 |
| P/S | 3.49x | US#1,900/3,118 Sec#128/203 |
| EV/EBITDA | 20.93x | US#2,005/3,118 Sec#95/203 |
| FCF Yield | 3.39% | US#1,712/3,118 Sec#95/203 |
| Profitability | ||
| ROE | 29.28% | US#310/3,118 Sec#14/203 |
| ROA | 10.36% | US#468/3,118 Sec#26/203 |
| Op. Margin | 12.21% | US#1,402/3,118 Sec#61/203 |
| Revenue Growth | 25.82% | US#495/3,118 Sec#29/203 |
| Earnings Growth | 111.69% | US#267/3,118 Sec#12/203 |
| Financial Health | ||
| Debt Ratio | 182.67% | US#1,694/3,118 Sec#146/203 |
| Total Debt | $868M | US#1,592/3,118 Sec#85/203 |
| FCF | $79M | US#1,824/3,118 Sec#108/203 |
| Cash | $473M | US#1,109/3,118 Sec#65/203 |
| Current Ratio | 6.63x | US#368/3,118 Sec#25/203 |
| Net Debt/EBITDA | 3.03x | US#1,703/3,118 Sec#107/203 |
| Performance | ||
| 1Y Return | -45.95% | US#2,885/3,118 Sec#187/203 |
| 1M Return | -15.53% | US#2,819/3,118 Sec#190/203 |
| From 52W High | -56.79% | US#2,793/3,118 Sec#187/203 |
| 1Y MDD | -58.76% | US#2,695/3,118 Sec#170/203 |
| Trading | ||
| Volume | 554,500 shares | US#1,810/3,118 Sec#127/203 |
| Trading Value | $37M | US#1,368/3,118 Sec#100/203 |
| Per Share | ||
| EPS | $4.39 | US#781/3,118 Sec#42/203 |
| BPS | $14.99 | US#1,524/3,118 Sec#84/203 |
Company Info
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.